EGFR and neoplasm: Because of the features of EBP binding to EGFR and the overexpression of EGFR in a wide variety of tumors, we previously designed a cytotoxic analogue that links doxorubicin (DOX) to EBP via an ester bond at DOX position 14 through a glutarate spacer and demonstrated that this conjugate had high affinity and specificity for EGFR-overexpressing tumor cells, resulting in enhanced antitumor efficacy and reduced systemic toxicity (18, 19).